MA42472B1 - Méthode pour l'amélioration de la solubilité aqueuse des agents actifs non-soluble ou mal soluble dans l'eau - Google Patents

Méthode pour l'amélioration de la solubilité aqueuse des agents actifs non-soluble ou mal soluble dans l'eau

Info

Publication number
MA42472B1
MA42472B1 MA42472A MA42472A MA42472B1 MA 42472 B1 MA42472 B1 MA 42472B1 MA 42472 A MA42472 A MA 42472A MA 42472 A MA42472 A MA 42472A MA 42472 B1 MA42472 B1 MA 42472B1
Authority
MA
Morocco
Prior art keywords
water
insoluble
dissolved
organic compound
aqueous solvent
Prior art date
Application number
MA42472A
Other languages
English (en)
French (fr)
Other versions
MA42472A (fr
Inventor
Andreas Grassauer
Eva Prieschl-Grassauer
Angelika Bodenteich
Martina Morokutti-Kurz
Sabine Nakowitsch
Cornelia Kaintz
Original Assignee
Marinomed Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinomed Biotech Ag filed Critical Marinomed Biotech Ag
Publication of MA42472A publication Critical patent/MA42472A/fr
Publication of MA42472B1 publication Critical patent/MA42472B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10General cosmetic use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
MA42472A 2015-07-16 2016-07-15 Méthode pour l'amélioration de la solubilité aqueuse des agents actifs non-soluble ou mal soluble dans l'eau MA42472B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201514801578A 2015-07-16 2015-07-16
PCT/EP2016/066999 WO2017009480A1 (en) 2015-07-16 2016-07-15 Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs

Publications (2)

Publication Number Publication Date
MA42472A MA42472A (fr) 2018-05-30
MA42472B1 true MA42472B1 (fr) 2021-02-26

Family

ID=56418519

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42472A MA42472B1 (fr) 2015-07-16 2016-07-15 Méthode pour l'amélioration de la solubilité aqueuse des agents actifs non-soluble ou mal soluble dans l'eau

Country Status (29)

Country Link
EP (1) EP3324933B1 (https=)
JP (1) JP6836825B2 (https=)
KR (1) KR102615005B1 (https=)
CN (1) CN107847440B (https=)
AU (1) AU2016293125B2 (https=)
CA (1) CA2992376C (https=)
CL (1) CL2018000032A1 (https=)
CO (1) CO2018001460A2 (https=)
CY (1) CY1124322T1 (https=)
DK (1) DK3324933T3 (https=)
EA (1) EA036233B1 (https=)
ES (1) ES2844581T3 (https=)
HR (1) HRP20210333T1 (https=)
HU (1) HUE053116T2 (https=)
IL (1) IL256882B (https=)
LT (1) LT3324933T (https=)
MA (1) MA42472B1 (https=)
MX (1) MX379341B (https=)
MY (1) MY196065A (https=)
NZ (1) NZ738592A (https=)
PH (1) PH12018500042A1 (https=)
PL (1) PL3324933T3 (https=)
PT (1) PT3324933T (https=)
RS (1) RS61561B1 (https=)
SA (1) SA518390688B1 (https=)
SI (1) SI3324933T1 (https=)
UA (1) UA123312C2 (https=)
WO (1) WO2017009480A1 (https=)
ZA (1) ZA201708594B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108143713A (zh) * 2018-01-04 2018-06-12 南方医科大学南方医院 一种增加羟喜树碱溶解度的方法
US12377046B1 (en) 2019-04-24 2025-08-05 Wellomics LLC Delivery system matrices
CN110074385B (zh) * 2019-05-21 2022-05-31 绥化市蓝源生物工程有限公司 一种生物碱溶解纳他霉素的生物溶剂及其应用
KR20220022829A (ko) * 2020-08-19 2022-02-28 주식회사 모든바이오 글리시리진 및 수용성 약물을 포함하는 나노 입자, 이를 포함하는 약제학적 조성물 및 이들의 제조 방법
CN114588118B (zh) * 2022-01-25 2023-05-23 武汉爱民制药股份有限公司 一种注射用七叶皂苷钠复方制剂
KR102922176B1 (ko) * 2022-07-08 2026-02-04 한국생산기술연구원 소수성 약물 전달을 위한 금-히알루론산 나노입자의 제조방법
EP4431082A1 (en) * 2023-03-13 2024-09-18 Marinomed Biotech AG Aqueous composition comprising budesonide
EP4516289A1 (en) 2023-08-30 2025-03-05 SPH Sine Pharmaceutical Laboratories Co., Ltd Antiviral nasal spray comprising favipiravir
CN117562911B (zh) * 2023-12-07 2024-06-04 海南医学院 化合物tigloside在制备治疗和/或预防骨关节炎药物中的用途
WO2025133675A1 (en) * 2023-12-20 2025-06-26 Melikoglu, Ahmet Method for producing nasal formulation comprising aescin and rutin
EP4696300A1 (en) 2024-08-14 2026-02-18 Marinomed Biotech AG Aqueous composition comprising fluticasone
KR102907892B1 (ko) * 2025-01-09 2026-01-12 주식회사 한바이오 가용성을 높인 피레스로이드계의 보건용 스프레이 살충제 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1119957A (en) 1979-12-04 1982-03-16 Martin Whitefield Steroid compositions
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
US4868170A (en) 1987-11-13 1989-09-19 E. R. Squibb & Sons, Inc. Steriod lotion formulation
JPH1025255A (ja) * 1996-07-11 1998-01-27 Taisho Pharmaceut Co Ltd 溶解性の改善された難溶性薬剤
FR2799369B1 (fr) 1999-10-08 2001-12-21 Oreal Association d'escine et de sulfate de dextran et son utilisation
US7125564B2 (en) 2001-02-16 2006-10-24 Lavipharm Laboratories, Inc. Water soluble and palatable complexes
JP4000283B2 (ja) * 2002-08-07 2007-10-31 丸善製薬株式会社 甘草油性抽出物の可溶化組成物、並びに飲料、液状調味料、化粧品及び医薬部外品
US7897587B2 (en) 2004-09-03 2011-03-01 Nycomed Us Inc. Topical dermatological formulations and use thereof
JP5128801B2 (ja) * 2006-10-16 2013-01-23 フロイント産業株式会社 高水分散性粉末とその製造方法
JP6265624B2 (ja) * 2012-05-11 2018-01-24 ロート製薬株式会社 ルリコナゾール含有外用医薬組成物
US9907846B2 (en) * 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
CN103271891B (zh) * 2013-04-28 2016-01-06 福建南方制药股份有限公司 人参皂苷纳米胶束及其制备方法、应用和药物组合物
CN103520081B (zh) * 2013-09-27 2015-10-28 无限极(中国)有限公司 一种调节皮肤免疫力、延缓皮肤老化的外用护肤品

Also Published As

Publication number Publication date
UA123312C2 (uk) 2021-03-17
BR112018000613A2 (pt) 2018-09-18
IL256882B (en) 2021-12-01
KR102615005B1 (ko) 2023-12-18
HK1253027A1 (zh) 2019-06-06
DK3324933T3 (da) 2021-01-18
PL3324933T3 (pl) 2021-08-02
IL256882A (en) 2018-03-29
EP3324933A1 (en) 2018-05-30
MY196065A (en) 2023-03-13
CY1124322T1 (el) 2022-07-22
PH12018500042A1 (en) 2018-07-09
ES2844581T3 (es) 2021-07-22
HRP20210333T1 (hr) 2021-04-16
ZA201708594B (en) 2019-06-26
EA036233B1 (ru) 2020-10-16
CA2992376A1 (en) 2017-01-19
HUE053116T2 (hu) 2021-06-28
EP3324933B1 (en) 2020-12-16
JP2019501861A (ja) 2019-01-24
CL2018000032A1 (es) 2018-11-16
WO2017009480A1 (en) 2017-01-19
EA201890194A1 (ru) 2018-10-31
CN107847440A (zh) 2018-03-27
CO2018001460A2 (es) 2018-05-10
SA518390688B1 (ar) 2022-03-13
SI3324933T1 (sl) 2021-04-30
MX2018000286A (es) 2018-02-19
AU2016293125B2 (en) 2021-05-06
MX379341B (es) 2025-03-10
CA2992376C (en) 2023-06-20
MA42472A (fr) 2018-05-30
NZ738592A (en) 2021-12-24
JP6836825B2 (ja) 2021-03-03
AU2016293125A1 (en) 2018-01-18
RS61561B1 (sr) 2021-04-29
CN107847440B (zh) 2021-06-25
KR20180054569A (ko) 2018-05-24
PT3324933T (pt) 2021-01-28
LT3324933T (lt) 2021-04-26

Similar Documents

Publication Publication Date Title
MA42472B1 (fr) Méthode pour l'amélioration de la solubilité aqueuse des agents actifs non-soluble ou mal soluble dans l'eau
El Asar et al. Selenium protection against mercury neurotoxicity: modulation of apoptosis and autophagy in the anterior pituitary
CN104173235B (zh) 一种含页岩油的复合祛痘制剂及其制备方法
Abdelrahman et al. Antioxidant and antiapoptotic effects of quercetin against ochratoxin A-induced nephrotoxicity in broiler chickens
Azu et al. Histomorphometric effects of Kigelia africana (Bignoniaceae) fruit extract on the testis following short-term treatment with cisplatin in male Sprague–Dawley rats
WO2010046726A1 (en) Xylitol esters and ethers applied as alternative emulsifiers, solvents, co-emulsifiers and preservative systems for pharmaceutical and cosmetic products
JP6051055B2 (ja) 皮膚外用組成物
JP2010022295A (ja) 霊芝エキスの製造方法、該方法により製造された霊芝エキス、及び該霊芝エキスの使用方法
EP3242674B1 (fr) Compositions contenant de la curcumine à biodisponibilité améliorée
Salem et al. Subchronic toxicity of propyl paraben in adult male rats
KR20200053250A (ko) 수용성이 증진된 고농도 egcg 수용액의 제조 방법
KR970020112A (ko) 결명자 추출물의 제조방법과 이들로된 항산화, 프리라디칼소거, 항돌연변이제 및 안(眼) 노화 방지 안질환예방제
JP2007204418A (ja) 皮膚外用剤
KR20180061008A (ko) 어성초, 금잔화 및 상황버섯의 추출 혼합물을 유효성분으로 함유하는 육모 촉진용 화장료 조성물
Sood et al. Impact of Fluopyram on Testicular Tissue Alterations and Sperm Characteristics of Male Albino Rats
Hegazy et al. Luteolin‐Loaded Chitosan Nanoparticles Attenuate Fenvalerate‐Induced Nephrotoxicity and Humoral Immune Suppression via NRF2/HO‐1 Activation and NF‐κB‐Mediated Inflammatory and Apoptotic Pathway Inhibition
Silawat et al. Terminalia chebula attenuates ischemia reperfusion induced progressive nephropathy in diabetic rats
Fatehi et al. Microbial Biotechnology & Vaccine Design
Panovska et al. Evaluation of antioxidant capacity of Micromeria cristata L. extracts.
PL440027A1 (pl) Sposób otrzymywania preparatu bakteriobójczego i grzybobójczego oraz preparat bakteriobójczy i grzybobójczy
Omar et al. PROTECTIVE EFFICIENCY OF CURCUMIN AND BONE MARROW MESENCHYMAL STEM CELLS OF NEPHROTOXICITY INDUCED BY BROMATE IN RATS
CN102763644A (zh) 一种氰霜唑微乳剂及其制备方法
Padumadasa et al. Antioxidant and Cytotoxic Activities of Proanthocyanidins of the Bark of Thespesia populnea (L.)
CN107974362A (zh) 一种有效物成分高、去污力强易运输的洗护用品
JP2013142083A (ja) ヨモギ抽出物含有組成物